TEK and diabetic eye disease: Among the angiogenic signaling cascades inhibited by 32-134D are the VEGF/KDR axis (currently targeted by the FDA-approved therapies for DME and PDR, ranibizumab, aflibercept, and brolucizumab, as well as the oncology drug bevacizumab, used off-label for the treatment of diabetic eye disease) as well as the ANGPT2/TIE2/VE-PTP cascade (currently targeted by faricimab, a bispecific antibody targeting both VEGF and ANGPT2 [refs. 58, 59], and AKB-9778, a subcutaneous VE-PTP inhibitor [refs. 60, 61]).